The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Exosomes derived from miR‐181‐5p‐modified adipose‐derived mesenchymal stem cells prevent liver fibrosis via autophagy activation
Open accessAbstract
Proliferating hepatic stellate cells (HSC s) respond to liver damage by secreting collagens that form fibrous scar tissue, which can lead to cirrhosis if in appropriately regulated. Advancement of micro RNA (mi RNA) hepatic therapies has been hampered by difficulties in delivering mi RNA to damaged tissue. However, exosomes secreted by adipose‐derived mesenchymal stem cells (ADSC s) can be exploited to deliver mi RNA s to HSC s. ADSC s were engineered to overexpress mi RNA‐181‐5p (miR‐181‐5p‐ADSC s) to selectively home exosomes to mouse hepatic stellate (HST‐T6) cells or a CC l4‐induced liver fibrosis murine model and compared with non‐targeting control Caenorhabditis elegans miR‐67 (cel‐miR‐67)‐ADSC s. In vitro analysis confirmed that the transfer of miR‐181‐5p from miR‐181‐5p‐ADSC s occurred via secreted exosomal uptake. Exosomes were visualized in HST‐T6 cells using cyc3‐labelled pre‐mi RNA‐transfected ADSC s with/without the exosomal inhibitor, GW 4869. The effects of mi RNA‐181‐5p overexpression on the fibrosis associated STAT 3/Bcl‐2/Beclin 1 pathway and components of the extracellular matrix were assessed. Exosomes from miR181‐5p‐ADSC s down‐regulated Stat3 and Bcl‐2 and activated autophagy in the HST‐T6 cells. Furthermore, the up‐regulated expression of fibrotic genes in HST‐T6 cells induced by TGF‐β1 was repressed following the addition of isolated miR181‐5p‐ADSC exosomes compared with miR‐67‐ADSC exosomes. Exosome therapy attenuated liver injury and significantly down‐regulated collagen I, vimentin, α‐SMA and fibronectin in liver, compared with controls. Taken together, the effective anti‐fibrotic function of engineered ADSC s is able to selectively transfer miR‐181‐5p to damaged liver cells and will pave the way for the use of exosome‐ADSC s for therapeutic delivery of mi RNA targeting liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Baglio, S. R., Rooijers, K., Koppers-Lalic, D., Verweij, F. J., Pérez Lanzón, M., Zini, N., Naaijkens, B., Perut, F., Niessen, H. W. M., Baldini, N., et al. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0116-z · Cited by 765
Lou, G., Song, X., Yang, F., Wu, S., Wang, J., Chen, Z., & Liu, Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0220-7 · Cited by 651
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Ji, J., Yamashita, T., Budhu, A., Forgues, M., Jia, H., Li, C., Deng, C., Wauthier, E., Reid, L. M., Ye, Q., et al. (2009) · Hepatology · doi:10.1002/hep.22989 · Cited by 532
Borges, F. T., Melo, S. A., Özdemir, B. C., Kato, N., Revuelta, I., Miller, C. A., Gattone, V. H., LeBleu, V. S., & Kalluri, R. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012101031 · Cited by 419
Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis
Wang, B., Yao, K., Huuskes, B. M., Shen, H.-H., Zhuang, J., Godson, C., Brennan, E. P., Wilkinson-Berka, J. L., Wise, A. F., & Ricardo, S. D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.90 · Cited by 379
Bhattacharya, S., Ray, R. M., & Johnson, L. R. (2005) · Biochemical Journal · doi:10.1042/bj20050465 · Cited by 291
Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases
Masyuk, A. I., Masyuk, T. V., & LaRusso, N. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.028 · Cited by 283
Cited by
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Brennan, M. Á., Layrolle, P., & Mooney, D. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909125 · Cited by 396
MSC exosome works through a protein-based mechanism of action
Toh, W. S., Lai, R. C., Zhang, B., & Lim, S. K. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180079 · Cited by 394
The Role of MSC in Wound Healing, Scarring and Regeneration
Guillamat-Prats, R. (2021) · Cells · doi:10.3390/cells10071729 · Cited by 393
Chen, S., Tang, Y., Liu, Y., Zhang, P., Lv, L., Zhang, X., Jia, L., & Zhou, Y. (2019) · Cell Proliferation · doi:10.1111/cpr.12669 · Cited by 344
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 329
Yamashita, T., Takahashi, Y., & Takakura, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00133 · Cited by 306
Qiu, G., Zheng, G., Ge, M., Wang, J., Huang, R., Shu, Q., & Xu, J. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1069-9 · Cited by 289
Joo, H. S., Suh, J. H., Lee, H. J., Bang, E. S., & Lee, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030727 · Cited by 284
Dabrowska, S., Andrzejewska, A., Janowski, M., & Lukomska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591065 · Cited by 282
Varderidou-Minasian, S., & Lorenowicz, M. J. (2020) · Theranostics · doi:10.7150/thno.40122 · Cited by 274
Hong, P., Yang, H., Wu, Y., Li, K., & Tang, Z. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1358-y · Cited by 269
Li, Y., Zhang, J., Shi, J., Liu, K., Wang, X., Jia, Y., He, T., Shen, K., Wang, Y., Liu, J., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02290-0 · Cited by 266
Luo, Q., Guo, D., Liu, G., Chen, G., Hang, M., & Jin, M. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485949 · Cited by 260
Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles
Park, K.-S., Bandeira, E., Shelke, G. V., Lässer, C., & Lötvall, J. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1398-3 · Cited by 256
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
Ma, Z.-J., Yang, J.-J., Lu, Y.-B., Liu, Z.-Y., & Wang, X.-X. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.814 · Cited by 155
Self-citationMesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury
Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01895-1 · Cited by 130
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82
Ashour, A. A., El-Kamel, A. H., Mehanna, R. A., Mourad, G., & Heikal, L. A. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2142700 · Cited by 60
Fang, J., & Liang, W. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.059 · Cited by 42
Techniques for increasing the yield of stem cell-derived exosomes: What factors may be involved?
Feng, Z.-Y., Zhang, Q.-Y., Tan, J., & Xie, H.-Q. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-1997-2 · Cited by 40
“Researchers have improved the therapeutic outcome of certain diseases by over-expressing bioactive compounds such as miR-181-5p (Qu et al., 2017), miR-214 (Shi et al., 2021), and miR-155-5p (Damasceno et al., 2020) in the MSCs. Sterzenbach et al. have fabricated a drug vector to penetrate the…”
BackgroundSelf-citationGupta, S., Pinky, Vishal, Sharma, H., Soni, N., Rao, E. P., Dalela, M., Yadav, A., Nautiyal, N., Kumar, A., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10313-9 · Cited by 35
Jun, J. H., Kim, J. Y., Choi, J. H., Lim, J.-Y., Kim, K., & Kim, G. J. (2020) · Stem Cells International · doi:10.1155/2020/5485738 · Cited by 33
The Crosstalk between Mesenchymal Stromal/Stem Cells and Hepatocytes in Homeostasis and under Stress
Kholodenko, I. V., Kholodenko, R. V., & Yarygin, K. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015212 · Cited by 16
Extracellular vesicles: emerging therapeutic agents for liver fibrosis
Chiabotto, G., Semnani, A., Ceccotti, E., & Bruno, S. (2025) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.08 · Cited by 13
Didamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Xie, Y., Yao, J., Yan, M., Lin, Y., Wei, J., Wang, H., Mao, Y., Liu, P., & Li, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04732-0 · Cited by 9
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
Metadata
- Authors
- Qu, Y., Zhang, Q., Cai, X., Li, F., Ma, Z., Xu, M., & Lu, L.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2017-04-06
- Volume
- 21
- Issue
- 10
- Pages
- 2491-2502
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2604116492
- Cited by
- 389
- References
- 28
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.